Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Inc (PRLD) is a clinical-stage biopharmaceutical company advancing precision oncology through targeted small molecule therapies. This dedicated news hub provides stakeholders with verified updates on clinical developments, research breakthroughs, and corporate milestones.
Find comprehensive coverage of PRLD's innovative pipeline including SMARCA2 protein degraders and selective CDK9 inhibitors, alongside strategic collaborations shaping cancer treatment paradigms. Our curated news selection prioritizes factual reporting on trial progress, regulatory communications, and partnership announcements without speculative content.
Key updates include phase 1 clinical data, scientific conference presentations, and manufacturing developments. Bookmark this page for efficient tracking of PRLD's progress in addressing high-unmet medical needs through molecularly targeted approaches.
Prelude Therapeutics (Nasdaq: PRLD) reported a net loss of $26.9M for Q2 2021, equating to $0.58 per share, a significant increase from a net loss of $11.4M, or $5.50 per share, in Q2 2020. The company has $343.1M in cash for ongoing clinical trials, including Phase 1 studies of PRT543, PRT811, and PRT1419. Upcoming milestones include data presentations at the AACR-NCI-EORTC Annual Meeting. R&D expenses rose to $22.4M, driven by increased clinical research costs, while G&A expenses rose to $5.5M due to personnel growth and professional fees.
Prelude Therapeutics (Nasdaq: PRLD) appointed Martin Babler to its Board of Directors, bringing over 25 years of biotech experience, including his role as CEO of Principia Biopharma until its acquisition in 2020. Mr. Babler will also serve on the Audit Committee. CEO Kris Vaddi emphasized the value of his expertise in driving the company's pipeline of cancer therapies. Prelude focuses on precision oncology, with candidates like PRT543 and PRT811 in clinical trials targeting significant cancer unmet needs.
Prelude Therapeutics (Nasdaq: PRLD) announced participation in two virtual investor conferences: the 42nd Annual Goldman Sachs Global Healthcare Conference with a fireside chat on June 9, 2021, at 8:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, at 10:00 a.m. ET. Live webcasts will be available on the company's website, with replays for a limited time. Prelude focuses on precision oncology with notable candidates like PRT543 for advanced solid tumors and PRT811 for glioblastoma.
Prelude Therapeutics (Nasdaq: PRLD) announced its Q1 2021 financial results and provided updates on clinical trials. Key developments include enrollment in multiple expansion cohorts for PRT543, a PRMT5 inhibitor, and ongoing dose escalation in PRT1419, an MCL1 inhibitor. Initial clinical data for PRT543 and PRT811 is expected in 2H21. As of March 31, 2021, the company reported $363 million in cash, with a net loss of $21.3 million or $0.47 per share. R&D expenses rose to $16.5 million. The company anticipates sufficient funds to support operations into 2023.
Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), has announced that CEO Kris Vaddi, PhD, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 p.m. ET. The presentation will be available via live webcast on the Company’s investor website, with a replay accessible later.
Prelude is developing innovative oral drug candidates for critical cancer pathways, including PRT543 and PRT811, both in Phase 1 trials targeting advanced tumors and glioblastoma. Their pipeline also includes PRT1419, a promising MCL1 inhibitor.
Prelude Therapeutics (Nasdaq: PRLD) reported its financial results for Q4 and full year 2020, highlighting a net loss of $19.3 million for Q4 and $56.9 million for the year. The company completed the dose escalation of its lead product PRT543 and plans to start expansion cohorts in Q2 2021. Prelude also announced ongoing trials for PRT1419 and PRT811, with anticipated data readouts in 2H21. The successful public offering raised $172.5 million, and cash reserves of $218.3 million are expected to support operations into 2023.
Prelude Therapeutics (Nasdaq: PRLD) announced management participation in three virtual investor conferences. Key details include:
- Barclays Global Healthcare Conference: March 10, 2021, at 8:35 a.m. ET.
- Morgan Stanley Virtual Healthcare Corporate Access Day: One-on-one meetings on March 16, 2021.
- Oppenheimer 31st Annual Healthcare Conference: March 17, 2021, at 3:50 p.m. ET.
Webcasts available on the company's website, where replays will also be accessible.
Prelude Therapeutics announced the completion of an upsized public offering, selling 2,583,334 shares of voting common stock and 291,666 shares of non-voting common stock at $60.00 per share, raising approximately $172.5 million in gross proceeds. This offering included the underwriters' full option for an additional 375,000 shares. The offering was managed by Morgan Stanley, Goldman Sachs, BofA Securities, and Barclays. Prelude develops precision oncology therapies, with candidates targeting PRMT5 and MCL1 pathways, currently in various phases of clinical trials.
Prelude Therapeutics has announced a public offering of 2,208,334 shares of voting common stock and 291,666 shares of non-voting common stock at $60.00 per share, aiming to raise approximately $150 million. The offering closes on January 11, 2021, with underwriters Morgan Stanley, Goldman Sachs, BofA Securities, and Barclays involved. A 30-day option for underwriters to purchase an additional 375,000 shares has been granted. This funding will support Prelude's clinical-stage oncology developments, including advanced candidates targeting critical cancer pathways.
Prelude Therapeutics (Nasdaq: PRLD) has initiated a public offering of 1,750,000 shares of common stock under a filed registration statement. The company will sell all shares, with a potential 30-day option for underwriters to purchase up to an additional 262,500 shares. The offering is led by Morgan Stanley, Goldman Sachs, BofA Securities, and Barclays. Completion of the offering is not guaranteed, as the registration statement with the SEC has yet to become effective, and no sales can occur until it does.
